Drug Treatment for Cutaneous T-cell Lymphoma Approved
The U.S. Food and Drug Administration has approved Gloucester Pharmaceuticals’ Istodax® (romidepsin), an injectable medication, for treatment of people with a rare form of cancer known as cutaneous T-cell lymphoma. People with localized CTCL on the skin are treated with topical agents or phototherapy, but chemotherapy may be used if the cancer advances. Istodax interferes with processes required for cell replication. It is intended to be used in people whose CTCL gets worse or comes back after at least one other type of chemotherapy has been used.
♦ ♦ ♦ ♦ ♦
This article was printed from copingmag.com and was originally published in Coping® with Cancer magazine, January/February 2010.